IGM-8444 is a monoclonal antibody commercialized by IGM Biosciences, with a leading Phase I program in Non-Hodgkin Lymphoma. According to Globaldata, it is involved in 2 clinical trials, which are ongoing. GlobalData uses proprietary data and analytics to provide a complete picture of IGM-8444’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.

Smarter leaders trust GlobalData

The revenue for IGM-8444 is expected to reach an annual total of $67 mn by 2039 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.

IGM-8444 Overview

IGM-8444 is under development for the treatment of relapsed or refractory non-Hodgkin’s lymphoma, solid tumors including colorectal cancer, sarcoma and relapsed or refractory chronic lymphocytic leukemia and acute myeloid leukemia. The drug candidate acts by targeting death receptor 5 (DR5). It is administered through intravenous route.

It was also under development for the treatment of metastatic prostate cancer, gastric cancer, ovarian cancer, non-small cell lung cancer.

IGM Biosciences Overview

IGM Biosciences operates as a biotechnology company that develops novel antibodies for the treatment of cancer and other diseases. The company’s pipeline product portfolio includes IGM-2323is an IgM-based CD20 x CD3 bispecific antibody T cell engager, IGM-8444 is an IgM antibody targeting Death Receptor, IGM-7354 is a targeted IL-15 immune stimulating antibody and IGM-2644 a T cell engaging IgM antibody targeting CD38 for the treatment of patients with multiple myeloma. It utilizes IgM and IgA antibodies technology for developing its products. IGM Biosciences is headquartered in Mountain View, California, the US.
The company reported revenues of (US Dollars) US$1.1 million for the fiscal year ended December 2022 (FY2022). The operating loss of the company was US$228 million in FY2022, compared to an operating loss of US$165.3 million in FY2021. The net loss of the company was US$221.1 million in FY2022, compared to a net loss of US$165.2 million in FY2021. The company reported revenues of US$0.5 million for the second quarter ended June 2023, a decrease of 14.2% over the previous quarter.

For a complete picture of IGM-8444’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.

This content was updated on 7 February 2024

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, drug margins and company expenses. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate valuation, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA) and phase transition success rate (PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.